TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04294056
Drug: Ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
Study: NCT04294056
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
Study: NCT01206322
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The acute effects of a single 40-IU dose of intranasal insulin
Study: NCT01250496
Drug: Aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of intravenous aminophylline
Study: NCT00003590
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg/day PO
Study: NCT00802113
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 x 5 days
Study: NCT00802113
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 3.2 mg/kg/day x 2 days
Study: NCT00802113
Drug: Anti-Thymocyte Globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
Study: NCT01697410
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
Study: NCT01589653
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
Study: NCT01589653
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
Study: NCT02303977
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02303977
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00027573
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00027573
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01205373
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral drinking solution
Study: NCT01262274
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANA is given 1mg daily for 24 weeks.
Study: NCT04332874
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
Study: NCT04332874
Drug: infusion of melphalan and dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion of melphalan and dactinomycin
Study: NCT01788813
Drug: GSK2245035
Normalized name: GSK2245035
DrugBank: GSK2245035 (DB16076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
Study: NCT05873907
Drug: AMG 592
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as SC injection
Study: NCT03557840
Drug: temocillin
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug dosing and blood sampling as per the protocol
Study: NCT04121169
Drug: IM-01
Normalized name: bimatoprost 0.01 MG
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
Study: NCT00006014
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03387423
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who are started on Tofacitinib treatment according to the drug label
Study: NCT00544349
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03572049
Drug: SUBA itraconazole
Normalized name: ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
Study: NCT03572049
Drug: Conventional itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
Study: NCT01680198
Drug: Paracalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
Study: NCT04610957
Drug: Rosafem (FEMININE FORMULA)
Normalized name: sulfacetamide sodium Medicated Liquid Soap [Rosaderm Cleanser]
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
Study: NCT04175990
Drug: Dydrogesterone Pill
Normalized name: dydrogesterone Pill
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: started from day 1 of menses till trigger day
Study: NCT02908490
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 50 mg once daily
Study: NCT03519542
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
Study: NCT01507064
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets 200mg dosage: 400mg bid duration: 4 weeks
Study: NCT01588756
Drug: AcSDKP-NH2 inuline
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once intravenous administration of 100 µg or less
Study: NCT01588756
Drug: AcSDKP-NH2 Cr-EDTA
Normalized name: GHRH(1-44)NH2
DrugBank: Somatorelin (DB12656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once intravenous administration of 100 µg or less
Study: NCT00447070
Drug: ATAZANAVIR
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02936661
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01579851
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations
Study: NCT02364336
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00918931
Drug: Obatoclax Mesylate
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
Study: NCT02195921
Drug: only antiemetic drug
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received routine antiemetic treatment
Study: NCT03530007
Drug: Ondansetron 4 MG
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 4 MG used for prevention of spinal shivering
Study: NCT03530007
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 8 MG used for prevention of spinal shivering
Study: NCT03246386
Drug: Posaconazole Injection [Noxafil] 300mg
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose by intravenous infusion 300mg
Study: NCT00056537
Drug: ABR-217620
Normalized name: ABR-90
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
Study: NCT03681561
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop.
Study: NCT03246386
Drug: Posaconazole Injection [Noxafil] 400mg
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose by intravenous infusion 400mg
Study: NCT00985777
Drug: Vitamin E δ-Tocotrienol
Normalized name: tocotrienols / vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
Study: NCT03681561
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
Study: NCT03493945
Drug: N-803
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-15 mcg/kg subcutaneous every 2 weeks
Study: NCT03493945
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg orally twice daily (1200 MG total)
Study: NCT00625664
Drug: larotaxel (XRP9881)
Normalized name: Larotaxel
DrugBank: Larotaxel (DB12984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered on day 1 as a 1-hour infusion
Study: NCT00625664
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered on day 1, 8 and 15 as a 30-minute infusion
Study: NCT00625664
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 hour infusion administered on day 1, 30 minutes after the other treatment
Study: NCT02513095
Drug: Dantrolene sodium for injectable suspension
Normalized name: Dantrolene Sodium for Injectable Suspension
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
Study: NCT02216214
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04495296
Drug: TST001
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN CLAUDIN 18.2) (HUMAN-MUS MUSCULUS MONOCLONAL TST001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TST001 .KAPPA.-CHAIN, DIMER
DrugBank: Osemitamab (DB18219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TST001 will be administered by specified doses on specified day
Study: NCT04495296
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered by specified doses on specified day
Study: NCT04495296
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered by specified doses on specified day
Study: NCT04495296
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered by specified doses on specified day
Study: NCT04495296
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
Study: NCT04495296
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered by specified doses on specified day
Study: NCT00227708
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00321581
Drug: Cediranib, AZD2171, RECENTIN
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01037621
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
Study: NCT01970280
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006049
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006049
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006049
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04408820
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral
Study: NCT03066011
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral and Intravenous
Study: NCT03066011
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral and Intravenous
Study: NCT03066011
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral and intravenous
Study: NCT06566391
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
Study: NCT01757873
Drug: Z160
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02992808
Drug: recombinant gonadotropins
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02684370
Drug: risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab administered by subcutaneous (SC) injection
Study: NCT01317550
Drug: Armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg by mouth once a day for a 10 week cycle.
Study: NCT02684370
Drug: placebo for risankizumab
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for risankizumab administered by subcutaneous (SC) injection
Study: NCT02684370
Drug: ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab administered by subcutaneous (SC) injection
Study: NCT02684370
Drug: placebo for ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for ustekinumab administered by subcutaneous (SC) injection
Study: NCT01523847
Drug: MBVD (Myocet+BVD)
Normalized name: BVdU
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15
Study: NCT03287271
Drug: VS-6063
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1:~* First 3 patient cohort: VS-6063 200 mg PO twice daily~* IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity.
Study: NCT03287271
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1:~* First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity.
Study: NCT03287271
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1:~* First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity.
Study: NCT04044690
Drug: human immunoglobulin G
Normalized name: Human immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human immunoglobulin G administered subcutaneously
Study: NCT04501861
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin (20 IU/100 ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
Study: NCT03992430
Drug: Eteplirsen
Normalized name: Eteplirsen
DrugBank: Eteplirsen (DB06014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for intravenous (IV) infusion.
Study: NCT01987570
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03255629
Drug: glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
Study: NCT01165424
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning.
Study: NCT00422058
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected s.c. (under the skin) once daily
Study: NCT00422058
Drug: orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg capsule. Administered thrice daily
Study: NCT00910624
Drug: Boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
Study: NCT00910624
Drug: Ribavirin (SCH 18908)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
Study: NCT04301310
Drug: BMS-986235 (Treatment A)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04301310
Drug: Rifampin (Treatment B)
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01378546
Drug: 3,4-diaminopyridine
Normalized name: 3,4-Diaminopyridine
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment will begin with 5mg three times a day or less.
Study: NCT02206295
Drug: selexipag
Normalized name: Selexipag
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01722058
Drug: Peptide application
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01232075
Drug: Extended letrozole regimen
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .